Pharmaceutical and Cosmetic Compositions Comprising PLGF-1
AssigneeGeymonat S.p.A.
InventorsDomenico Maglione, Mauro Battisti, Ettore Conti, Giuseppe Salvia, Marina Tucci
Life of this patent
Estimating the term…
Abstract
Abstract of the Disclosure The invention relates to the preparation of placental growth factor (PLGF)-comprising therapeutic and cosmetic compositions capable of increasing angiogenesis of the cutaneous, subcutaneous and internal organ connective tissue. Such compositions are suitable for the treatment of pathological or natural states benefiting from the formation or regeneration of new vessels of the cutaneous compartment, such as seleroderma, its various manifestations, skin ageing or loss of hair.
Claims35
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
Cancelled.
A method of use of type 1 Placental Growth Factor (PLGF-1) comprising preparing a medicament that comprises PLGF-1 as an active principle, wherein said medicament promotes angiogenesis in the treatment of a state selected from the group consisting of:
- diseases and pathological alterations involving the cutaneous or subcutaneous connective tissues,
- scleroderma, and
- early skin ageing due to exposure to atmospheric aggressive agents or to protracted solar irradiation.
A method of use of type 1 Placental Growth Factor (PLGF-1) comprising administering PLGF-1 to promote cutaneous or subcutaneous angiogenesis in the prevention and cosmetic treatment of natural skin ageing.
A method of use of type 1 Placental Growth Factor (PLGF-1) comprising administering PLGF-1 to promote perifollicolar angiogenesis in the prevention and in the cosmetic treatment of the natural loss of hair.
A pharmaceutical composition comprising PLGF-1 as active principle and a pharmaceutically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 50 µg to 30 mg per unitary dose for parenteral use and in an amount from 0.1 mg to 10 mg per gram of composition for topical use.
A cosmetic composition comprising PLGF-1 as active principle and a cosmetically acceptable excipient, wherein at least 98.5% of the PLGF-1 is in active dimeric and multimeric form, at least 70% is in dimeric form and no more than 1.5% is in monomeric form, and wherein PLGF-1 is comprised in an amount from 0.01 mg to 0.09 mg per gram of composition.
Dependencies are inferred from the claim text.